The effects of canrenone on inflammatory markers in patients with metabolic syndrome

Giuseppe Derosa, Davide Romano, Lucio Bianchi, Angela D'angelo, Pamela Maffioli

Research output: Contribution to journalArticle

Abstract

Aim. To evaluate the effects of canrenone compared to placebo on blood pressure control, some non-conventional biomarkers in cardiovascular stratification, and on metalloproteinases in patients affected by metabolic syndrome. Methods. A total of 156 Caucasian patients were treated with placebo or canrenone, 50 mg once a day, for 3 months and then 50 mg twice a day, till the end of the study. We evaluated: systolic (SBP) and diastolic blood pressure (DBP), body weight, body mass index (BMI), fasting plasma glucose (FPG), lipid profile, plasma aldosterone, creatinine, potassium, brain natriuretic peptide (BNP), metalloproteinases 2 and 9 (MMP-2 and -9), lipoprotein (a) (Lp(a)), and serum myeloperoxidase (MPO). Results. We observed a significant decrease of SBP and DBP in the canrenone group compared to baseline. Canrenone gave a significant decrease of MMP-2 and -9, Lp(a), and MPO compared to baseline, not observed with placebo. Plasma aldosterone, but not BNP, decreased with canrenone, both compared to baseline and to placebo. Conclusion. Canrenone seems to be effective in reducing blood pressure in patients with metabolic syndrome. Moreover, canrenone seems also to improve MPO, Lp(a), and metalloproteinases in these patients.

Original languageEnglish
Pages (from-to)47-52
Number of pages6
JournalAnnals of Medicine
Volume47
Issue number1
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

Canrenone
Blood Pressure
Lipoprotein(a)
Placebos
Peroxidase
Brain Natriuretic Peptide
Metalloproteases
Aldosterone
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Matrix Metalloproteinases
Fasting
Creatinine
Potassium
Body Mass Index
Biomarkers
Body Weight
Lipids
Glucose

Keywords

  • Canrenone
  • Inflammatory markers
  • Metalloproteinases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The effects of canrenone on inflammatory markers in patients with metabolic syndrome. / Derosa, Giuseppe; Romano, Davide; Bianchi, Lucio; D'angelo, Angela; Maffioli, Pamela.

In: Annals of Medicine, Vol. 47, No. 1, 01.02.2015, p. 47-52.

Research output: Contribution to journalArticle

@article{a0830b0c3c5e49de8af0754133ae2187,
title = "The effects of canrenone on inflammatory markers in patients with metabolic syndrome",
abstract = "Aim. To evaluate the effects of canrenone compared to placebo on blood pressure control, some non-conventional biomarkers in cardiovascular stratification, and on metalloproteinases in patients affected by metabolic syndrome. Methods. A total of 156 Caucasian patients were treated with placebo or canrenone, 50 mg once a day, for 3 months and then 50 mg twice a day, till the end of the study. We evaluated: systolic (SBP) and diastolic blood pressure (DBP), body weight, body mass index (BMI), fasting plasma glucose (FPG), lipid profile, plasma aldosterone, creatinine, potassium, brain natriuretic peptide (BNP), metalloproteinases 2 and 9 (MMP-2 and -9), lipoprotein (a) (Lp(a)), and serum myeloperoxidase (MPO). Results. We observed a significant decrease of SBP and DBP in the canrenone group compared to baseline. Canrenone gave a significant decrease of MMP-2 and -9, Lp(a), and MPO compared to baseline, not observed with placebo. Plasma aldosterone, but not BNP, decreased with canrenone, both compared to baseline and to placebo. Conclusion. Canrenone seems to be effective in reducing blood pressure in patients with metabolic syndrome. Moreover, canrenone seems also to improve MPO, Lp(a), and metalloproteinases in these patients.",
keywords = "Canrenone, Inflammatory markers, Metalloproteinases",
author = "Giuseppe Derosa and Davide Romano and Lucio Bianchi and Angela D'angelo and Pamela Maffioli",
year = "2015",
month = "2",
day = "1",
doi = "10.3109/07853890.2014.969303",
language = "English",
volume = "47",
pages = "47--52",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - The effects of canrenone on inflammatory markers in patients with metabolic syndrome

AU - Derosa, Giuseppe

AU - Romano, Davide

AU - Bianchi, Lucio

AU - D'angelo, Angela

AU - Maffioli, Pamela

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Aim. To evaluate the effects of canrenone compared to placebo on blood pressure control, some non-conventional biomarkers in cardiovascular stratification, and on metalloproteinases in patients affected by metabolic syndrome. Methods. A total of 156 Caucasian patients were treated with placebo or canrenone, 50 mg once a day, for 3 months and then 50 mg twice a day, till the end of the study. We evaluated: systolic (SBP) and diastolic blood pressure (DBP), body weight, body mass index (BMI), fasting plasma glucose (FPG), lipid profile, plasma aldosterone, creatinine, potassium, brain natriuretic peptide (BNP), metalloproteinases 2 and 9 (MMP-2 and -9), lipoprotein (a) (Lp(a)), and serum myeloperoxidase (MPO). Results. We observed a significant decrease of SBP and DBP in the canrenone group compared to baseline. Canrenone gave a significant decrease of MMP-2 and -9, Lp(a), and MPO compared to baseline, not observed with placebo. Plasma aldosterone, but not BNP, decreased with canrenone, both compared to baseline and to placebo. Conclusion. Canrenone seems to be effective in reducing blood pressure in patients with metabolic syndrome. Moreover, canrenone seems also to improve MPO, Lp(a), and metalloproteinases in these patients.

AB - Aim. To evaluate the effects of canrenone compared to placebo on blood pressure control, some non-conventional biomarkers in cardiovascular stratification, and on metalloproteinases in patients affected by metabolic syndrome. Methods. A total of 156 Caucasian patients were treated with placebo or canrenone, 50 mg once a day, for 3 months and then 50 mg twice a day, till the end of the study. We evaluated: systolic (SBP) and diastolic blood pressure (DBP), body weight, body mass index (BMI), fasting plasma glucose (FPG), lipid profile, plasma aldosterone, creatinine, potassium, brain natriuretic peptide (BNP), metalloproteinases 2 and 9 (MMP-2 and -9), lipoprotein (a) (Lp(a)), and serum myeloperoxidase (MPO). Results. We observed a significant decrease of SBP and DBP in the canrenone group compared to baseline. Canrenone gave a significant decrease of MMP-2 and -9, Lp(a), and MPO compared to baseline, not observed with placebo. Plasma aldosterone, but not BNP, decreased with canrenone, both compared to baseline and to placebo. Conclusion. Canrenone seems to be effective in reducing blood pressure in patients with metabolic syndrome. Moreover, canrenone seems also to improve MPO, Lp(a), and metalloproteinases in these patients.

KW - Canrenone

KW - Inflammatory markers

KW - Metalloproteinases

UR - http://www.scopus.com/inward/record.url?scp=84923310377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923310377&partnerID=8YFLogxK

U2 - 10.3109/07853890.2014.969303

DO - 10.3109/07853890.2014.969303

M3 - Article

C2 - 25319120

AN - SCOPUS:84923310377

VL - 47

SP - 47

EP - 52

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

IS - 1

ER -